Info

21. Schlossman R, Alyea E, Orsini E, Anderson K: Immune based strategies to improve hematopoietic stem cell transplantation in mulitple myeloma. In: Dicke K, Keating A, eds. Autologous Marrow and Blood Transplantation. Charlottesville, VA: Carden, Jennings Publishing; 1999:207-221.

22. Reece DE, Shepherd JD, Klingemann HG, et al.: Treatment of myeloma using intensive therapy and allo-geneic Stem cell transplantation. Stem cell Transplant 15:117-123, 1995.

23. Bjorkstrand B, Ljungman P, Svensson H, et al.: Allogeneic Stem cell transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88:4711-4718, 1996.

24. Alyea E, Weller E, Schlossman R, et al.: Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Stem cell Transplant 32:1145-1151, 2003.

25. Martinelli G, Terragna C, Zamagni E, et al.: Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 18:2273-2281, 2000.

26. Cavo M, Terragna C, Martinelli G, et al.: Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 96:355-357, 2000.

27. Kroger N, Einsele H, Wolff D, et al.: Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study Group Multiple Myeloma (DSMM). Stem cell Transplant 31:973-979, 2003.

28. Lokhorst HM, Segeren CM, Verdonck LF, et al.: Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol 21:1728-1733, 2003.

29. Russell NH, Miflin G, Stainer C, et al.: Allogeneic Stem cell transplant for multiple myeloma [letter]. Blood 89:2610-2611, 1997.

30. Bensinger WI, Demirer T, Buckner CD, et al.: Syngeneic marrow transplantation in patients with multiple myeloma. Stem cell Transplant 18:527-531, 1996.

31. Gahrton G, Svensson H, Bjorkstrand B, et al.: Syngeneic transplantation in multiple myeloma—a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Stem cell Transplant 24:741-745, 1999.

32. Bensinger WI, Weaver CH, Appelbaum FR, et al.: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant granulocyte colony-stimulating factor. Blood 85:1655-1658, 1995.

33. Majolino I, Corradini P, Scime R, et al.: Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Stem cell Transplant 22:449-455, 1998.

34. Mehta J, Tricot G, Jagannath S, et al.: Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Stem cell Transplant 21:887-892, 1998.

35. Couban S, Stewart AK, Loach D, Panzarella T, Meharchand J: Autologous and allogeneic transplantation for multiple myeloma at a single centre. Stem cell Transplant 19:783-789, 1997.

36. Reynolds C, Ratanatharathorn V, Adams P, et al.: Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Stem cell Transplant 27:801-807, 2001.

37. Kwak LW, Taub DD, Duffey PL, et al.: Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345:1016-1020, 1995.

38. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF: Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic Stem cell transplantation. Blood 90:4206-4211, 1997.

39. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus-myeloma effect: proof of principle. Blood 87:1196-1198, 1996.

40. Alyea EP, Soiffer RJ, Canning C, et al.: Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic Stem cell transplant. Blood 91:3671-3680, 1998.

41. Mehta J, Singhal S: Graft-versus-myeloma. Stem cell Transplant 22:835-843, 1998.

42. Salama M, Nevill T, Marcellus D, et al.: Donor leukocyte infusions for multiple myeloma. Stem cell Transplant 26:1179-1184, 2000.

43. Huff CA, Fuchs EJ, Noga SJ, et al.: Long-term follow-up of T cell-depleted allogeneic Stem cell transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biol Blood Marrow Transplant 9:312-319, 2003.

44. Peggs KS, Thomson K, Hart DP, et al.: Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 103:1548-1556, 2004.

45. Byrne JL, Fairbairn J, Davy B, Carter IG, Bessell EM, Russell NH: Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission. Stem cell Transplant 31:157-161, 2003.

46. Voena C, Malnati M, Majolino I, et al.: Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. Stem cell Transplant 32:791-793, 2003.

47. Giralt S, Hester J, Huh Y, et al.: CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic Stem cell transplantation. Blood 86:4337-4343, 1995.

48. Bonini C, Verzeletti S, Servida P, et al.: Transfer of the HSV-TK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor antitumor immunity after ALLO- SCT (meeting abstract). Blood 84:110a, 1994.

49. Bonini C, Ferrari G, Verzeletti S, et al.: HSV-TK gene transfer into donor lymphocytes for control of allo-geneic graft-versus-leukemia [see comments]. Science 276:1719-1724, 1997.

50. Link CJ Jr, Traynor A, Seregina T, Burt RK: Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene. Cancer Treat Res 101:369-375, 1999.

51. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al.: Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome.

J Clin Oncol 18:3031-3037, 2000.

52. Lokhorst HM, Wu K, Verdonck LF, et al.: The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 103:4362-4364, 2004.

53. Alyea E, Schossman R, Canning C, et al.: CD6 T cell depleted allogeneic Stem cell transplant followed by CD4+ donor lymphocyte infusion for patients with multiple myeloma. Blood 94:609a, 1999.

54. Badros A, Barlogie B, Siegel E, et al.: Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 20:1295-1303, 2002.

55. Giralt S, Weber D, Cohen A, et al.: Non Myeloablative Conditioning with Fludarabine and Melphalan for Patients with Multiple Myeloma. Keystone, CO: ASBMT; 1999:43.

56. Kroger N, Sayer HG, Schwerdtfeger R, et al.: Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 100:3919-3924, 2002.

57. Kroger N, Schwerdfeger R, Kiehl M, et al.: Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in muti-ple myeloma. Blood 100(3):755-760, 2002.

58. Maloney DG, Molina AJ, Sahebi F, et al.: Allografting with nonmyeloablative conditioning following cytore-ductive autografts for the treatment of patients with multiple myeloma. Blood 102:3447-3454, 2003.

59. Peggs KS, Mackinnon S, Williams CD, et al.: Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 9:257-265, 2003.

60. Lee CK, Badros A, Barlogie B, et al.: Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 31:73-80, 2003.

61. Kroger N, Schilling G, Einsele H, et al.: Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 103:4056-4061, 2004.

62 Takahashi T, Makiguchi Y, Hinoda Y, et al.: Expression of MUC1 on myeloma cells and induction of HLA-unre-stricted CTL against MUC1 from a multiple myeloma patient. J Immunol 153:2102-2109, 1994.

63. van Baren N, Brasseur F, Godelaine D, et al.: Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 94:1156-1164, 1999.

64. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673-679, 1999.

65. Bellucci R, Wu CJ, Chiaretti S, et al.: Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood 103:656-663, 2004.

66. Osterborg A, Yi Q, Henriksson L, et al.: Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 91: 2459-2466, 1998.

67 Massaia M, Borrione P, Battaglio S, et al.: Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 94:673-683, 1999.

68. Barratt-Boyes SM: Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol Immunother 43:142-151, 1996.

69. Noto H, Takahashi T, Makiguchi Y, Hayashi T, Hinoda Y, Imai K: Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Int Immunol 9:791-798, 1997.

70. Tanaka Y, Koido S, Chen D, Gendler SJ, Kufe D, Gong J: Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol 101:192-200, 2001.

71. Brossart P, Heinrich KS, Stuhler G, et al.: Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:4309-4317, 1999.

72. Orsini E, Alyea EP, Schlossman R, et al.: Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Stem cell Transplant 25:623-632, 2000.

73. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV: Antitumor monoclonal antibodies enhance cross-presentation of Cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195:125-133, 2002.

74. Nishikawa H, Tanida K, Ikeda H, et al.: Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc Natl Acad Sci US A 98:14571-14576, 2001.

75. Sahin U, Tureci O, Schmitt H, et al.: Human neoplasms elicit multiple specific immune responses in the autolo-gous host. Proc Natl Acad Sci U S A 92:11810-11813, 1995.

76. Old LJ, Chen YT: New paths in human cancer serology. J Exp Med 187:1163-1167, 1998.

77. Wu CJ, Yang XF, McLaughlin S, et al.: Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 106:705-714, 2000.

78. Sahin U, Tureci O, Pfreundschuh M: Serological identification of human tumor antigens. Curr Opin Immunol 9:709-716, 1997.

79. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC: CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 85:1903-1912, 1995.

80. Schultze JL, Cardoso AA, Freeman GJ, et al.: Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity [published erratum appears in Proc Natl Acad Sci U S A 92(23):10818, 1995 Nov 7]. Proc Natl Acad Sci U S A 92:8200-8204, 1995.

81. Teoh G, Tai Y-T, Greenfield E, Anderson K: Tumor rejection antigen 1 (GRP94) expression is induced by CD40 ligand activation of multiple myeloma cells and mediates allogeneic T cell reactivity [abstract]. Blood. In press.

82. Janson CH, Grunewald J, Osterborg A, et al.: Predominant T cell receptor V gene usage in patients with abnormal clones of B cells. Blood 77:1776-1780, 1991.

83. Dianzani U, Pileri A, Boccadoro M, et al.: Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood 72:1064-1068, 1988.

84. Moss P, Gillespie G, Frodsham P, Bell J, Reyburn H: Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia. Blood 87:3297-3306, 1996.

85. Osterborg A, Masucci M, Bergenbrant S, Holm G, Lefvert AK, Mellstedt H: Generation of T cell clones binding F(ab')2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy. Cancer Immunol Immunother 34:157-162, 1991.

86. Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK: Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 86: 3043-3049, 1995.

87. Osterborg A, Yi Q, Bergenbrant S, Holm G, Lefvert AK, Mellstedt H: Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. Br J Haematol 89:110-116, 1995.

88. Yi Q, Holm G, Lefvert AK: Idiotype-induced T cell stimulation requires antigen presentation in association with HLA-DR molecules. Clin Exp Immunol 104:359-365, 1996.

89. Bergenbrant S, Yi Q, Osterborg A, et al.: Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol 92:840-846, 1996.

90. Reichardt VL, Okada CY, Liso A, et al.: Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma— a feasibility study. Blood 93:2411-2419, 1999.

91. Kwak LW, Pennington R, Longo DL: Active immunization of murine allogeneic Stem cell transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts. Blood 87:3053-3060, 1996.

0 0

Post a comment